Martin Schuler

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Martin Schuler
May 30, 2025, 06:35 | Blog
Jay Bradner: Molecular Determinants of Sotorasib Clinical Efficacy in KRASG12C-NSCLC
Jay Bradner, Executive Vice President of R&D, and Chief Scientific Officer at Amgen, posted on…
May 29, 2025, 17:09 | Science
Stephen Liu: Molecular Determinants of Efficacy with Sotorasib in KRASG12C NSCLC by Ferdinandos Skoulidis et al.
Stephen Liu, Director of Thoracic Oncology, Head of Developmental Therapeutics, and Associate Professor at the…
May 29, 2025, 14:15 | Insight
New Biomarker May Guide Best Use of KRAS Inhibitors in Lung Cancer
Lung cancer patients with high TTF-1 expression had improved survival outcomes following treatment with the…
May 11, 2025, 13:57 | Science
Giannis Mountzios: Shedding Light on Factors Influencing Treatment Sequence in BRAF Mutant NSCLC
Giannis Mountzios, Director of the 4th Oncology Department and Clinical Trials Unit at Henry Dunant…
May 9, 2025, 15:02 | Science
Aakash Desai: New insights in BRAFV600–mutated NSCLC
Aakash Desai, Assistant Professor and Associate Director of Phase 1 and Precision Oncology Program at the…
May 9, 2025, 12:14 | Blog
Aakash Desai Highlights New Study on BRAF-Mutated NSCLC: Personalization Over One-Size-Fits-All
Aakash Desai, Assistant Professor and Associate Director of Phase 1 and Precision Oncology Program at…
Jan 8, 2025, 14:32 | Blog
Aakash Desai: Autogene cevumeran redefining personalized cancer treatment
Aakash Desai, Assistant Professor at UAB O’Neal Comprehensive Cancer Center, shared on LinkedIn: "mRNA-based Immunotherapy…
Dec 29, 2024, 11:07 | Science
The highest cited original research publications in Pancreatic Cancer from 2020 to 2024 by Anirban Maitra
Anirban Maitra, Professor of Pathology and Translational Molecular Pathology at UT MD Anderson Cancer Center,…
Jun 29, 2024, 14:04 | Insight
Piotr Wysocki: Combination of nivolumab and relatlimab in neoadjuvant setting in resectable NSCLC
Piotr Wysocki recently posted on LinkedIn: "Martin Schuler et al. published results of their phase 2…
All: 9 Posts: 1 - 100
Special Coverage